Aldeyra Therapeutics will submit a FDRR to the FDA for reproxalap, an investigational drug or dry eye disease.
|Videos|January 22, 2020
Dry Eye Patient (A)
Author(s)Jade Coats, OD, FAAO
Advertisement
Dry eye video provided by Jade Coats, OD.
Systemic disease and autoimmune conditions are frequently associated with an increased risk of dry eye syndrome. These patients are often affected by a combination of both evaporative and aqueous deficient dry eye; therefore, cognizance of a patient’s entire health history can help lead ODs to the root cause of chronic DES. Click on the following link to read more:
Advertisement
Related to this article
Coats explains how neurotrophic keratitis, Demodex blepharitis, cosmetic habits, and mucus fishing complicate dry eye disease.
Ashraf Ahmad, MD, explains what's driving rising dry eye rates and why eyelid evaluation is often overlooked.
Ashraf Ahmad, MD, explains what tear breakup time testing shows and why results vary between clinic visits.
Catch up on the top stories in optometry during the week of September 7-September 11.
Startup S5G Therapeutics aims to move ubiquinol technology from the laboratory toward treatments for dry eye, Fuchs dystrophy, and other corneal conditions.
The latest in drug and technology developments and updates from August 2026.
Periocular skin treatment is emerging as a complementary treatment for dry eye disease.
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
Johnson & Johnson Acuvue Oasys lenses demonstrate favorable moisture retention
2
AAOpt 2026: CLI releases full contact lens profitability report
3
Aldeyra to appeal FDA rejection of reproxalap as a treatment for dry eye disease
4
EyeCon 2026: Jade Coats, OD, FAAO, on dry eye disease comorbidities
5